Bill Addressing High Drug Prices Advances
Assembly will take up bipartisan legislation, amendments, on Tuesday.
Pharmacy benefit managers, or PBMs, negotiate prices with drug manufacturers on behalf of insurers. They also process claims and keep a list of what drugs will be covered by insurance.
According to the National Academy for State Health Policy, 114 bills regulating pharmacy benefit managers are working their way through legislatures across the country.
A bipartisan bill sponsored by Rep. Michael Schraa, R-Oshkosh, and Sen. Jon Erpenbach, D-West Point, is scheduled to be taken up Tuesday by the Wisconsin Assembly after getting committee approval Thursday.
While the vote Thursday to send the bill to the full floor for a vote was unanimous, some Democrats objected, saying the bill had been watered down with amendments.
“I thought the bill we had originally provided the most consumer protections and the most protections for our small pharmacies,” said committee member Rep. Deb Kolste, D-Janesville.
Groups that sought to protect patients from what they say are harmful practices by PBMs are behind the bill and hope it becomes law.
“It moves the ball forward. It puts us in a better place than we are now,” said Rob Gundermann, president and CEO of the Coalition of Wisconsin Aging and Health Groups.
In a 2017 report, drugmakers contend one reason it seems as if the costs of medicines are going up dramatically is because discounts and rebates provided by brand manufacturers do not flow directly to the patients taking the medicine but are instead given to health plans.
Insurers often use the rebates and discounts they receive to help reduce the cost of health plans or premiums, though they are not required to do so.
The Wisconsin bill is designed to add transparency to the process by regulating PBMs under the Office of the Commissioner of Insurance. The proposal would also allow pharmacists to tell customers about cheaper options, including paying cash if their insurance co-payment is larger. Currently, many PBMs prevent that with so-called gag rules. More than half the states in the United States have laws against gag rules.
“Elimination of the gag clause is really important,” Gundermann said.
Additionally, under the bill there would be fewer instances where PBMs could deny a claim. PBMs could still change their list of approved drugs throughout the year, a practice consumer groups had hoped to end. If the PBM substitutes one drug for another, under the bill it would have to give health insurers and customers 30 days notice.
Listen to the WPR report here.
Wisconsin Drug Pricing Bill Makes Headway was originally published by Wisconsin Public Radio.